Dominick J Angiolillo

Dominick J Angiolillo, M.D., Ph.D.

Professor; Chief, Division Of Cardiology; Medical Director, UF Health Cardiovascular Center – Jacksonville; Medical Director, Cardiovascular Research Program; Program Director, Interventional Cardiology Fellowship

Department: Medicine – Jacksonville
Business Phone: (904) 244-2655

About Dominick J Angiolillo

Dominick J. Angiolillo, M.D., Ph.D., is Chief of the Division of Cardiology and Medical Director of the UF Health Cardiovascular Center. Dr. Angiolillo graduated summa cum laude from the Catholic University of the Sacred Heart Medical School in Rome, Italy, where he completed training in medicine and cardiology. He then pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology. In 2004, Dr. Angiolillo joined the University of Florida College of Medicine – Jacksonville, where he is a professor of medicine with tenure status, director of cardiovascular research and director of the interventional cardiology fellowship program. He is staff cardiologist and interventional cardiologist on the UF Health Jacksonville campus. Dr. Angiolillo is board-certified in cardiovascular disease and interventional cardiology.

Much of Dr. Angiolillo’s professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. In particular, Dr. Angiolillo has performed seminal studies on platelet function and modulation of antiplatelet drug response, including genetic studies. He has received national and international academic recognitions for this work. Recognitions include the 2013 Outstanding Achievement Award from the European Society of Cardiology and, since 2014, Dr. Angiolillo has been in the top 1 percent of most-cited researchers worldwide, according to Clarivate Analytics. Dr. Angiolillo has been a key investigator in the clinical development of numerous novel antithrombotic agents. He works alongside drug-regulating agencies in the United States and Europe toward approval of these drugs and product labeling updates. His success in obtaining extramural funding has allowed the development of one of the most active clinical research centers in the U.S. as well as one of the leading centers for thrombosis research in the world.

Dr. Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as cardiovascular medicine textbooks. He has authored more than 650 peer-reviewed articles, with over 60,000 citations and an H-index of 107. He has authored more than 35 book chapters and is the editor of his own textbook on antithrombotic medicine. Due to his major contributions in antithrombotic therapy in patients with cardiovascular disease manifestations, Dr. Angiolillo has been invited to deliver lectures worldwide. His international visibility has allowed him to develop a very active research training program, attracting physicians and scientists from across the globe. In addition, Dr. Angiolillo has been a clinical mentor for years to residents and fellows, resulting in several Exemplary Teacher Awards. His leadership role as an academic clinician and scientist allows to him to nurture and promote career growth of many young trainees in the United States and abroad.

Dr. Angiolillo is an active member of many cardiovascular societies in the U.S. and Europe. In addition, he serves on the editorial board of numerous cardiovascular journals, some of which he holds leadership roles. He is a scientific reviewer for many major journals and extramural funding agencies, including the National Institutes of Health and other federal funding agencies in several European countries.

Additional Positions:
Chief
2021 – Current · UF Division of Cardiology – Jacksonville
Medical Director
2021 – Current · UF Health Cardiovascular Center
Professor
2015 – Current · University of Florida
Program Director
2015 – Current · Interventional Cardiology Fellowship
Medical Director
2010 – Current · Cardiovascular Research Program
Related Links:

Accomplishments

Highly Cited Researchers
2020 · Clarivate
10-Year Service Pin
2018 · University of Florida College of Medicine – Jacksonville
Highly Cited Researchers
2018 · Clarivate
Highly Cited Researchers
2017 · Clarivate
University of Florida Research Foundation Professorship
2017 · University of Florida
Cardiovascular Disease Exam Committee
2016 · American Board of Internal Medicine
Simon Dack Award for Outstanding Scholarship
2016 · American College of Cardiology
The World’s Most Influential Scientific Minds
2016 · Thomas Reuters
Simon Dack Award for Outstanding Scholarship
2015 · American College of Cardiology
Outstanding Achievement Award
2013 · European Society of Cardiology

Board Certifications

  • Cardiovascular Disease
    American Board of Internal Medicine
  • Interventional Cardiology
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Internal Medicine
Subspecialties
  • Cardiology
  • Interventional Cardiology
Areas of Interest
  • Acute coronary syndrome
  • Angioplasty and stent placement – heart
  • Cardiac catheterization
  • Cardiac intravascular ultrasound
  • Coronary heart disease
  • Deep vein thrombosis
  • Heart and vascular services
  • Heart attack
  • Heart disease
  • Heparin coated coronary artery stent

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0001-8451-2131

Publications

2024
1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program.
The American journal of cardiology. 214:94-104 [DOI] 10.1016/j.amjcard.2023.12.049. [PMID] 38185438.
2024
Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers.
Cardiovascular drugs and therapy. 38(1):181-189 [DOI] 10.1007/s10557-022-07358-4. [PMID] 35715526.
2024
Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines.
European heart journal. Acute cardiovascular care. 13(1):173-180 [DOI] 10.1093/ehjacc/zuad158. [PMID] 38170562.
2024
Aspirin hypersensitivity and intolerance.
European heart journal. Cardiovascular pharmacotherapy. [DOI] 10.1093/ehjcvp/pvae008. [PMID] 38268418.
2024
Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis.
European heart journal. Cardiovascular pharmacotherapy. 10(2):158-169 [DOI] 10.1093/ehjcvp/pvad085. [PMID] 37960983.
2024
Nonadherence to dual antiplatelet therapy: old problems without new solutions.
Revista espanola de cardiologia (English ed.). 77(2):125-128 [DOI] 10.1016/j.rec.2023.08.003. [PMID] 37659651.
2024
North American perspective on the 2023 European Society of Cardiology guidelines for the management of acute coronary syndromes
European Heart Journal: Acute Cardiovascular Care. 13(1):165-172 [DOI] 10.1093/ehjacc/zuad153.
2024
Optimizing LDL-cholesterol management in ACS patients: Breaking inertia and implementing intensified therapies.
International journal of cardiology. 400 [DOI] 10.1016/j.ijcard.2024.131803. [PMID] 38262483.
2024
Reply: Decoding Ticagrelor Dyspnea: Central Apnea Screening Before Drug Discontinuation.
JACC. Cardiovascular interventions. 17(3):452-453 [DOI] 10.1016/j.jcin.2023.12.035. [PMID] 38355276.
2024
Role of the P2Y12 receptor on thrombus formation and evolution in therapeutic strategies.
Expert opinion on therapeutic targets. 1-4 [DOI] 10.1080/14728222.2024.2315017. [PMID] 38315098.
2024
When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review.
Journal of the American College of Cardiology. 83(3):444-465 [DOI] 10.1016/j.jacc.2023.10.038. [PMID] 38233019.
2023
1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI.
JACC. Cardiovascular interventions. 16(20):2498-2510 [DOI] 10.1016/j.jcin.2023.08.014. [PMID] 37804290.
2023
Adjusted mortality of extracorporeal membrane oxygenation for acute myocardial infarction patients in cardiogenic shock.
Medicine. 102(11) [DOI] 10.1097/MD.0000000000033221. [PMID] 36930119.
2023
Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Expert Opinion on Pharmacotherapy. 24(4):453-471 [DOI] 10.1080/14656566.2023.2171788.
2023
Antithrombotic Therapy in Arterial Thrombosis and Thromboembolism in COVID-19: An American College of Chest Physicians Expert Panel Report.
Chest. 164(6):1531-1550 [DOI] 10.1016/j.chest.2023.06.032. [PMID] 37392958.
2023
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease.
European heart journal. Cardiovascular pharmacotherapy. 9(5):462-496 [DOI] 10.1093/ehjcvp/pvad032. [PMID] 37120728.
2023
Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
Thrombosis and Haemostasis. 123(4):464-477 [DOI] 10.1055/a-1988-5047. [PMID] 36442805.
2023
Author Correction: Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction
Nature Reviews Cardiology. [DOI] 10.1038/s41569-023-00974-z.
2023
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT.
International journal of cardiology. 383:24-32 [DOI] 10.1016/j.ijcard.2023.04.027. [PMID] 37080466.
2023
Bivalirudin in acute coronary syndromes
Expert Review of Cardiovascular Therapy. 21(12):901-911 [DOI] 10.1080/14779072.2023.2273902.
2023
Bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome.
European heart journal. Cardiovascular pharmacotherapy. 9(7):666-668 [DOI] 10.1093/ehjcvp/pvad029. [PMID] 37081774.
2023
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions.
Journal of the American College of Cardiology. 82(8):687-700 [DOI] 10.1016/j.jacc.2023.05.062. [PMID] 37587580.
2023
Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management
Expert Opinion on Drug Safety. 22(12):1193-1212 [DOI] 10.1080/14740338.2023.2291865.
2023
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.
JACC. Cardiovascular interventions. 16(1):36-46 [DOI] 10.1016/j.jcin.2022.10.034. [PMID] 36317958.
2023
Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of Bentracimab.
Clinical pharmacokinetics. 62(5):673-692 [DOI] 10.1007/s40262-023-01245-3. [PMID] 37118383.
2023
Clinical Pharmacokinetics and Pharmacodynamics of CSL112
Clinical Pharmacokinetics. 62(4):541-558 [DOI] 10.1007/s40262-023-01224-8. [PMID] 36928983.
2023
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial.
The American journal of cardiology. 208:16-24 [DOI] 10.1016/j.amjcard.2023.09.008. [PMID] 37806185.
2023
Considerations on the Management of Acute Postoperative Ischemia After Cardiac Surgery: A Scientific Statement From the American Heart Association.
Circulation. 148(5):442-454 [DOI] 10.1161/CIR.0000000000001154. [PMID] 37345559.
2023
Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction
Nature Reviews Cardiology. [DOI] 10.1038/s41569-023-00953-4.
2023
Correction to: Clinical Pharmacokinetics and Pharmacodynamics of CSL112
Clinical Pharmacokinetics. 62(7):1043-1043 [DOI] 10.1007/s40262-023-01277-9.
2023
COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment.
Seminars in thrombosis and hemostasis. 49(8):816-832 [DOI] 10.1055/s-0042-1757634. [PMID] 36223804.
2023
DAPT guided by platelet function tests or genotyping after PCI: pros and cons.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 19(7):546-548 [DOI] 10.4244/EIJ-E-23-00022. [PMID] 37720965.
2023
Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium
Circulation. 147(25):1933-1944 [DOI] 10.1161/circulationaha.123.064473.
2023
Differences Among Clinical Trials and Registries on Surgical and Percutaneous Coronary Interventions.
The Annals of thoracic surgery. 115(1):79-86 [DOI] 10.1016/j.athoracsur.2022.05.015. [PMID] 35643330.
2023
Direct Stenting versus Conventional Stenting in Patients with ST-Segment Elevation Myocardial Infarction-A COMPARE CRUSH Sub-Study.
Journal of clinical medicine. 12(20) [DOI] 10.3390/jcm12206645. [PMID] 37892785.
2023
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications
Expert Review of Clinical Pharmacology. 16(1):27-38 [DOI] 10.1080/17512433.2023.2154651.
2023
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions. 16(20):2514-2524 [DOI] 10.1016/j.jcin.2023.08.019. [PMID] 37879803.
2023
Editorial: Precision medicine for antithrombotic therapy in patients after percutaneous coronary interventions.
Frontiers in cardiovascular medicine. 10 [DOI] 10.3389/fcvm.2023.1162630. [PMID] 36937928.
2023
Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapy.
Minerva cardiology and angiology. [DOI] 10.23736/S2724-5683.23.06411-6. [PMID] 37870424.
2023
Efficacy and safety of lidocaine vs. opioid analgesics in acute coronary syndromes
European Heart Journal. Acute Cardiovascular Care. 12(1):12-13 [DOI] 10.1093/ehjacc/zuac157.
2023
European practice patterns for antiplatelet management in NSTE-ACS patients: Results from the REal-world ADoption survey focus on Acute antiPlatelet Treatment (READAPT) survey.
International journal of cardiology. 386:8-16 [DOI] 10.1016/j.ijcard.2023.05.025. [PMID] 37201617.
2023
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration
Expert Opinion on Drug Metabolism & Toxicology. 19(11):769-784 [DOI] 10.1080/17425255.2023.2272595.
2023
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics. 113(3):615-623 [DOI] 10.1002/cpt.2776. [PMID] 36306392.
2023
External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis.
European heart journal. Cardiovascular pharmacotherapy. 9(8):709-721 [DOI] 10.1093/ehjcvp/pvad063. [PMID] 37634083.
2023
Factor XI inhibitors in adjunct to antiplatelet therapy: the ultimate dual-pathway inhibition?
Bleeding, Thrombosis, and Vascular Biology. 2(3) [DOI] 10.4081/btvb.2023.90.
2023
Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis
Thrombosis and Haemostasis. 123(06):576-584 [DOI] 10.1055/a-2043-0346.
2023
Gender differences in efficacy and safety of antiplatelet strategies for acute coronary syndromes
Expert Opinion on Drug Safety. 22(8):669-683 [DOI] 10.1080/14740338.2023.2245331.
2023
How is pharmacogenetics changing clinical trial design for percutaneous coronary intervention?
Expert Review of Clinical Pharmacology. 16(5):383-385 [DOI] 10.1080/17512433.2023.2203381.
2023
Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy
Arteriosclerosis, Thrombosis, and Vascular Biology. 43(2) [DOI] 10.1161/atvbaha.122.318614.
2023
Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 18(15):1254-1265 [DOI] 10.4244/EIJ-D-22-00719. [PMID] 36602868.
2023
Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes.
Vascular pharmacology. 149 [DOI] 10.1016/j.vph.2023.107145. [PMID] 36720377.
2023
Long-Term Clopidogrel Monotherapy After Percutaneous Coronary Intervention: Will the Pupil Surpass the Master?
Journal of the American College of Cardiology. 82(16):1579-1582 [DOI] 10.1016/j.jacc.2023.08.035. [PMID] 37821167.
2023
Long-Term P2Y 12 Inhibitor or Aspirin as Single Antiplatelet Therapy in Patients With Previous Percutaneous Coronary Intervention
Circulation. 147(2):118-121 [DOI] 10.1161/circulationaha.122.063004.
2023
Long-term survival after cardiac arrest in patients undergoing emergent coronary angiography.
Cardiovascular revascularization medicine : including molecular interventions. [DOI] 10.1016/j.carrev.2023.09.008. [PMID] 37793964.
2023
Monitoring antiplatelet therapy: where are we now?
Journal of cardiovascular medicine (Hagerstown, Md.). 24(Suppl 1):e24-e35 [DOI] 10.2459/JCM.0000000000001406. [PMID] 36729588.
2023
Oral P2Y12 inhibiting therapy in patients with acute coronary syndrome: finding the sweet spot
European Heart Journal. 44(3):236-236 [DOI] 10.1093/eurheartj/ehac601.
2023
P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study.
JACC. Cardiovascular interventions. 16(15):1845-1855 [DOI] 10.1016/j.jcin.2023.05.035. [PMID] 37587591.
2023
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions.
Journal of the American College of Cardiology. 81(6):537-552 [DOI] 10.1016/j.jacc.2022.11.041. [PMID] 36754514.
2023
P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 19(4):e323-e329 [DOI] 10.4244/EIJ-D-23-00125. [PMID] 37306039.
2023
Personalised antiplatelet therapies for coronary artery disease: what the future holds
European Heart Journal. 44(32):3059-3072 [DOI] 10.1093/eurheartj/ehad362.
2023
Revascularization strategies versus optimal medical therapy in chronic coronary syndrome: A network meta-analysis.
International journal of cardiology. 370:58-64 [DOI] 10.1016/j.ijcard.2022.10.023. [PMID] 36265647.
2023
Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding.
European heart journal. 44(20):1780-1794 [DOI] 10.1093/eurheartj/ehad119. [PMID] 36988155.
2023
Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention.
Trends in cardiovascular medicine. 33(3):133-138 [DOI] 10.1016/j.tcm.2021.12.007. [PMID] 34936903.
2023
Sex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarction.
American heart journal. 258:17-26 [DOI] 10.1016/j.ahj.2022.12.013. [PMID] 36596332.
2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.
JACC. Cardiovascular interventions. 16(20):2528-2539 [DOI] 10.1016/j.jcin.2023.08.009. [PMID] 37609698.
2023
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study
Thrombosis and Haemostasis. 124(3):263-273 [DOI] 10.1055/a-2098-6639.
2023
The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromes.
European heart journal. Cardiovascular pharmacotherapy. 9(3):231-239 [DOI] 10.1093/ehjcvp/pvac067. [PMID] 36434779.
2023
The evaluation and management of coagulopathies in the intensive therapy units.
European heart journal. Acute cardiovascular care. 12(6):399-407 [DOI] 10.1093/ehjacc/zuad051. [PMID] 37172025.
2023
Ticagrelor Enhances the Cardioprotective Effects of Ischemic Preconditioning in Stable Patients Undergoing Percutaneous Coronary Intervention: the TAPER-S Randomized Study.
European heart journal. Cardiovascular pharmacotherapy. [DOI] 10.1093/ehjcvp/pvad092. [PMID] 38006237.
2023
Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial.
Clinical research in cardiology : official journal of the German Cardiac Society. 112(4):518-528 [DOI] 10.1007/s00392-022-02040-z. [PMID] 35789430.
2023
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial.
European heart journal. Cardiovascular pharmacotherapy. 9(4):328-336 [DOI] 10.1093/ehjcvp/pvad006. [PMID] 36649694.
2023
Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI.
JACC. Cardiovascular interventions. 16(1):1-18 [DOI] 10.1016/j.jcin.2022.10.023. [PMID] 36599574.
2023
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC).
European heart journal. Cardiovascular pharmacotherapy. 9(3):271-290 [DOI] 10.1093/ehjcvp/pvad016. [PMID] 36869784.
2022
CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
Journal of the American Heart Association. 11(4) [DOI] 10.1161/jaha.121.024159.
2022
A Comprehensive Review of the Pleiotropic Effects of Ticagrelor.
Cardiovascular drugs and therapy. [DOI] 10.1007/s10557-022-07373-5. [PMID] 36001200.
2022
ABCD‐GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR‐PCI Trial
Journal of the American Heart Association. 11(4) [DOI] 10.1161/jaha.121.024156.
2022
Antiplatelet therapy after percutaneous coronary intervention.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 17(17):e1371-e1396 [DOI] 10.4244/EIJ-D-21-00904. [PMID] 35354550.
2022
Approaches to de-escalation of antiplatelet treatment in stabilized post-myocardial infarction patients with high ischemic risk
Expert Review of Cardiovascular Therapy. 20(10):839-849 [DOI] 10.1080/14779072.2022.2137492.
2022
Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis.
JAMA. 328(6):554-562 [DOI] 10.1001/jama.2022.11966. [PMID] 35943473.
2022
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery.
NEJM evidence. 1(3) [DOI] 10.1056/EVIDoa2100047. [PMID] 38319214.
2022
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index.
JACC. Cardiovascular interventions. 15(19):1948-1960 [DOI] 10.1016/j.jcin.2022.07.039. [PMID] 36202563.
2022
Bleeding avoidance strategies in percutaneous coronary intervention
Nature Reviews Cardiology. 19(2):117-132 [DOI] 10.1038/s41569-021-00598-1.
2022
Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes.
Revista espanola de cardiologia (English ed.). 75(9):747-755 [DOI] 10.1016/j.rec.2021.11.007. [PMID] 34961732.
2022
Cangrelor Use Patterns and Transition to Oral P2Y 12 Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry
Journal of the American Heart Association. 11(11) [DOI] 10.1161/jaha.121.024513.
2022
Cilostazol: a Review of Basic Mechanisms and Clinical Uses.
Cardiovascular drugs and therapy. 36(4):777-792 [DOI] 10.1007/s10557-021-07187-x. [PMID] 33860901.
2022
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
European Heart Journal. 43(10):959-967 [DOI] 10.1093/eurheartj/ehab836. [PMID] 34918066.
2022
De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?
Frontiers in cardiovascular medicine. 9 [DOI] 10.3389/fcvm.2022.975969. [PMID] 36093167.
2022
Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta-analysis.
American heart journal. 250:1-10 [DOI] 10.1016/j.ahj.2022.04.004. [PMID] 35436504.
2022
Dual Versus Triple Antithrombotic Therapy for Atrial Fibrillation-ACS/PCI: One Size Does Not Fit All
Cardiovascular Revascularization Medicine. 43:152-154 [DOI] 10.1016/j.carrev.2022.06.003.
2022
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.
JAMA cardiology. 7(7):747-759 [DOI] 10.1001/jamacardio.2022.1292. [PMID] 35648414.
2022
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials.
European heart journal. Cardiovascular pharmacotherapy. 8(5):519-528 [DOI] 10.1093/ehjcvp/pvab043. [PMID] 34146091.
2022
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice.
Journal of clinical medicine. 11(21) [DOI] 10.3390/jcm11216246. [PMID] 36362474.
2022
Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week.
European heart journal. 43(37):3512-3527 [DOI] 10.1093/eurheartj/ehac294. [PMID] 35925556.
2022
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis.
European heart journal. Cardiovascular pharmacotherapy. 8(5):492-502 [DOI] 10.1093/ehjcvp/pvab068. [PMID] 34459481.
2022
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
European heart journal. Cardiovascular pharmacotherapy. 8(5):452-461 [DOI] 10.1093/ehjcvp/pvab042. [PMID] 34114623.
2022
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Journal of thrombosis and thrombolysis. 54(3):461-469 [DOI] 10.1007/s11239-022-02696-4. [PMID] 36048358.
2022
Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.
European heart journal. Cardiovascular pharmacotherapy. 8(1):4-12 [DOI] 10.1093/ehjcvp/pvaa095. [PMID] 32730628.
2022
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
Clinical pharmacology and therapeutics. 112(1):146-155 [DOI] 10.1002/cpt.2612. [PMID] 35429163.
2022
One-year cardiovascular outcomes after coronavirus disease 2019: The cardiovascular COVID-19 registry.
PloS one. 17(12) [DOI] 10.1371/journal.pone.0279333. [PMID] 36583998.
2022
Optimal antiplatelet therapy in patients at high bleeding risk undergoing complex percutaneous coronary intervention
European Heart Journal. 43(33):3115-3117 [DOI] 10.1093/eurheartj/ehac369.
2022
Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events.
European heart journal. Cardiovascular pharmacotherapy. 8(4):383-391 [DOI] 10.1093/ehjcvp/pvab062. [PMID] 34374741.
2022
P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention.
Journal of cardiovascular development and disease. 9(10) [DOI] 10.3390/jcdd9100340. [PMID] 36286292.
2022
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention
Nature Reviews Cardiology. 19(12):829-844 [DOI] 10.1038/s41569-022-00725-6.
2022
Patients With Atrial Fibrillation and PCI or ACS: Does Predicted Risk Matter?
Journal of the American College of Cardiology. 79(5):428-431 [DOI] 10.1016/j.jacc.2021.11.034. [PMID] 35115098.
2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease
Thrombosis and Haemostasis. 122(8):1341-1351 [DOI] 10.1055/a-1730-8725.
2022
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
Clinical Pharmacokinetics. 61(4):465-479 [DOI] 10.1007/s40262-021-01090-2. [PMID] 35060092.
2022
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
Journal of Thrombosis and Thrombolysis. 54(3):373-381 [DOI] 10.1007/s11239-022-02687-5. [PMID] 36036856.
2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy
European Heart Journal – Cardiovascular Pharmacotherapy. 8(7):728-737 [DOI] 10.1093/ehjcvp/pvac022.
2022
Pre-hospital treatment with crushed versus integral tablets of prasugrel in patients presenting with ST-Segment Elevation Myocardial Infarction-1-year follow-up results of the COMPARE CRUSH trial.
American heart journal. 252:26-30 [DOI] 10.1016/j.ahj.2022.05.022. [PMID] 35671829.
2022
Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention
Pharmacogenomics. 23(13):723-737 [DOI] 10.2217/pgs-2022-0057.
2022
Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in patients with Spontaneous Coronary Artery Dissection) randomized clinical trial.
Revista espanola de cardiologia (English ed.). 75(6):515-522 [DOI] 10.1016/j.rec.2021.08.003. [PMID] 34561195.
2022
Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.
JACC. Cardiovascular interventions. 15(9):999-1000 [DOI] 10.1016/j.jcin.2022.03.030. [PMID] 35512924.
2022
Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention: Only These 2 Options?
JACC. Cardiovascular interventions. 15(8):903-904 [DOI] 10.1016/j.jcin.2022.03.007. [PMID] 35450693.
2022
Reply: The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?
JACC. Cardiovascular interventions. 15(2):230-231 [DOI] 10.1016/j.jcin.2021.12.002. [PMID] 35057998.
2022
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
European Heart Journal – Cardiovascular Pharmacotherapy. 8(7):677-686 [DOI] 10.1093/ehjcvp/pvab070. [PMID] 34519777.
2022
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 17(16):1330-1339 [DOI] 10.4244/EIJ-D-21-00721. [PMID] 34881696.
2022
Septal perforating artery originating from the ramus intermedius artery.
Coronary artery disease. 31(1):e13-e14 [DOI] 10.1097/MCA.0000000000001059. [PMID] 34086613.
2022
Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.
JACC. Cardiovascular interventions. 15(3):268-277 [DOI] 10.1016/j.jcin.2021.11.028. [PMID] 35144783.
2022
The search for optimal antithrombotic therapy in transcatheter aortic valve implantation: facts and uncertainties.
European heart journal. 43(44):4616-4634 [DOI] 10.1093/eurheartj/ehac385. [PMID] 36130256.
2022
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy.
JACC. Cardiovascular interventions. 15(3):282-293 [DOI] 10.1016/j.jcin.2021.11.005. [PMID] 35033468.
2022
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.
European heart journal. Cardiovascular pharmacotherapy. 8(7):707-716 [DOI] 10.1093/ehjcvp/pvac016. [PMID] 35325085.
2022
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk
Circulation: Cardiovascular Interventions. 15(10) [DOI] 10.1161/circinterventions.122.012204.
2022
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 18(11):e897-e909 [DOI] 10.4244/EIJ-D-22-00319. [PMID] 35979636.
2022
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy
Circulation: Cardiovascular Interventions. 15(4) [DOI] 10.1161/circinterventions.120.009495.
2022
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19
European Heart Journal – Cardiovascular Pharmacotherapy. 8(3):E15-E17 [DOI] 10.1093/ehjcvp/pvac010. [PMID] 35108396.
2021
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation.
JACC. Cardiovascular interventions. 14(17):1870-1883 [DOI] 10.1016/j.jcin.2021.07.016. [PMID] 34503737.
2021
Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials.
Minerva cardiology and angiology. 69(4):398-407 [DOI] 10.23736/S2724-5683.20.05353-0. [PMID] 33258563.
2021
Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials.
Current opinion in cardiology. 36(4):390-396 [DOI] 10.1097/HCO.0000000000000879. [PMID] 33973929.
2021
Antithrombotic Management of Elderly Patients With Coronary Artery Disease.
JACC. Cardiovascular interventions. 14(7):723-738 [DOI] 10.1016/j.jcin.2021.01.040. [PMID] 33826494.
2021
Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 17(1):59-66 [DOI] 10.4244/EIJ-D-20-00885. [PMID] 32928716.
2021
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement.
JACC. Cardiovascular interventions. 14(15):1688-1703 [DOI] 10.1016/j.jcin.2021.06.020. [PMID] 34353601.
2021
Antithrombotic therapy in diabetes: which, when, and for how long?
European heart journal. 42(23):2235-2259 [DOI] 10.1093/eurheartj/ehab128. [PMID] 33764414.
2021
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease
Circulation. 144(16):1323-1343 [DOI] 10.1161/circulationaha.121.054305.
2021
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
Circulation. 143(6):583-596 [DOI] 10.1161/circulationaha.120.050438.
2021
Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events
Expert Review of Cardiovascular Therapy. 19(12):1097-1117 [DOI] 10.1080/14779072.2021.2020100.
2021
Aspirin for Primary Prevention of Cardiovascular Disease in the 21st Century: A Review of the Evidence.
The American journal of cardiology. 144 Suppl 1:S15-S22 [DOI] 10.1016/j.amjcard.2020.12.022. [PMID] 33706985.
2021
Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week.
Journal of the American College of Cardiology. 78(15):1550-1563 [DOI] 10.1016/j.jacc.2021.08.013. [PMID] 34620413.
2021
Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI.
International journal of cardiology. 328:40-45 [DOI] 10.1016/j.ijcard.2020.11.042. [PMID] 33242504.
2021
Canakinumab for secondary prevention of coronary artery disease
Future Cardiology. 17(3):427-442 [DOI] 10.2217/fca-2020-0211.
2021
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
Journal of the American Heart Association. 10(13) [DOI] 10.1161/jaha.121.022125.
2021
Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 98(6):1111-1119 [DOI] 10.1002/ccd.29314. [PMID] 33038061.
2021
Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management
Journal of the American Heart Association. 10(3) [DOI] 10.1161/jaha.120.019650.
2021
Dabigatran-based dual antithrombotic therapy for patients with atrial fibrillation and ST-elevation myocardial infarction undergoing percutaneous coronary intervention.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 17(6):443-444 [DOI] 10.4244/EIJV17I6A79. [PMID] 34413007.
2021
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
American heart journal. 231:147-156 [DOI] 10.1016/j.ahj.2020.09.019. [PMID] 33031789.
2021
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Journal of the American College of Cardiology. 78(21):2060-2072 [DOI] 10.1016/j.jacc.2021.08.074. [PMID] 34794687.
2021
Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.
BMJ open diabetes research & care. 9(1) [DOI] 10.1136/bmjdrc-2020-001939. [PMID] 33637605.
2021
Evidence and Recommendations for Uninterrupted Versus Interrupted Oral Anticoagulation in Patients Undergoing Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions. 14(7):764-767 [DOI] 10.1016/j.jcin.2021.02.019. [PMID] 33826496.
2021
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations
Expert Review of Clinical Pharmacology. 14(8):963-978 [DOI] 10.1080/17512433.2021.1927709. [PMID] 33993817.
2021
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Lancet (London, England). 397(10283):1470-1483 [DOI] 10.1016/S0140-6736(21)00533-X. [PMID] 33865495.
2021
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI.
JACC. Cardiovascular interventions. 14(13):1434-1446 [DOI] 10.1016/j.jcin.2021.04.043. [PMID] 34238553.
2021
Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies.
Journal of thrombosis and thrombolysis. 52(2):419-428 [DOI] 10.1007/s11239-020-02321-2. [PMID] 33709255.
2021
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics. 109(3):705-715 [DOI] 10.1002/cpt.2039. [PMID] 32897581.
2021
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.
JACC. Cardiovascular interventions. 14(21):2410-2412 [DOI] 10.1016/j.jcin.2021.07.051. [PMID] 34736741.
2021
Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus.
Frontiers in pharmacology. 12 [DOI] 10.3389/fphar.2021.695961. [PMID] 34239442.
2021
Letter by Angiolillo et al Regarding Article, “Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial”
Circulation. 143(13) [DOI] 10.1161/circulationaha.120.050205.
2021
Methodologic Considerations on Four Cardiovascular Interventions Trials With Contradictory Results.
The Annals of thoracic surgery. 111(2):690-699 [DOI] 10.1016/j.athoracsur.2020.04.107. [PMID] 32540434.
2021
MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation.
Journal of thrombosis and thrombolysis. 51(3):625-632 [DOI] 10.1007/s11239-020-02214-4. [PMID] 32803738.
2021
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management
Nature Reviews Cardiology. 18(1):37-57 [DOI] 10.1038/s41569-020-0410-z.
2021
Non-opioid analgesics in patients undergoing percutaneous coronary intervention: hype or hope?
European Heart Journal. 42(39):4037-4039 [DOI] 10.1093/eurheartj/ehab595.
2021
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.
BMJ (Clinical research ed.). 373 [DOI] 10.1136/bmj.n1332. [PMID] 34135011.
2021
Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction.
JACC. Cardiovascular interventions. 14(12):1323-1333 [DOI] 10.1016/j.jcin.2021.04.022. [PMID] 34167672.
2021
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
Journal of the American Heart Association. 10(4) [DOI] 10.1161/jaha.120.017008.
2021
Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention.
International journal of cardiology. 337:1-8 [DOI] 10.1016/j.ijcard.2021.05.012. [PMID] 34000356.
2021
Safety and efficacy of P2Y12inhibitor monotherapy in patients undergoing percutaneous coronary interventions
Expert Opinion on Drug Safety. 20(1):9-21 [DOI] 10.1080/14740338.2021.1850691.
2021
Severe, Intolerable Fatigue Associated with Hyperresponse to Clopidogrel.
World neurosurgery. 156:e374-e380 [DOI] 10.1016/j.wneu.2021.09.075. [PMID] 34563718.
2021
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.
JAMA cardiology. 6(9):1032-1041 [DOI] 10.1001/jamacardio.2021.1720. [PMID] 33991416.
2021
Systematic Assessment of Online Health Information for Coronary Revascularization.
JAMA internal medicine. 181(7):1003-1006 [DOI] 10.1001/jamainternmed.2021.1051. [PMID] 33871563.
2021
Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention
Expert Review of Cardiovascular Therapy. 19(6):519-535 [DOI] 10.1080/14779072.2021.1920925.
2021
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease.
Thrombosis and haemostasis. 121(4):422-432 [DOI] 10.1055/s-0040-1718729. [PMID] 33171520.
2021
The Role of Antiplatelet Therapy in Patients With MINOCA.
Frontiers in cardiovascular medicine. 8 [DOI] 10.3389/fcvm.2021.821297. [PMID] 35237672.
2021
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.
European heart journal. 42(45):4624-4634 [DOI] 10.1093/eurheartj/ehab702. [PMID] 34662382.
2021
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD.
European heart journal. 42(45):4683-4693 [DOI] 10.1093/eurheartj/ehab533. [PMID] 34423374.
2021
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis.
JACC. Cardiovascular interventions. 14(4):444-456 [DOI] 10.1016/j.jcin.2020.11.046. [PMID] 33602441.
2021
Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.
JAMA cardiology. 6(10):1121-1129 [DOI] 10.1001/jamacardio.2021.2228. [PMID] 34190967.
2021
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate.
JACC. Cardiovascular interventions. 14(17):1857-1866 [DOI] 10.1016/j.jcin.2021.06.028. [PMID] 34446390.
2021
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor
Journal of Thrombosis and Thrombolysis. 51(3):741-747 [DOI] 10.1007/s11239-021-02386-7. [PMID] 33582955.
2020
Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial.
Annals of internal medicine. 173(6):436-444 [DOI] 10.7326/M20-1806. [PMID] 32687741.
2020
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus
Expert Review of Cardiovascular Therapy. 18(8):449-464 [DOI] 10.1080/14779072.2020.1792293.
2020
Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience.
TH open : companion journal to thrombosis and haemostasis. 4(4):e437-e445 [DOI] 10.1055/s-0040-1721504. [PMID] 33376943.
2020
Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus.
Circulation. 142(22):2172-2188 [DOI] 10.1161/CIRCULATIONAHA.120.045465. [PMID] 33253005.
2020
Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation
Journal of Thrombosis and Thrombolysis. 49(3):337-343 [DOI] 10.1007/s11239-020-02051-5. [PMID] 32080811.
2020
Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.
Clinical and translational science. 13(3):473-481 [DOI] 10.1111/cts.12729. [PMID] 31758664.
2020
Clopidogrel drug interactions: a review of the evidence and clinical implications
Expert Opinion on Drug Metabolism & Toxicology. 16(11):1079-1096 [DOI] 10.1080/17425255.2020.1814254.
2020
COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
American heart journal. 224:10-16 [DOI] 10.1016/j.ahj.2020.03.005. [PMID] 32272255.
2020
Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in medicine : official journal of the American College of Medical Genetics. 22(11) [DOI] 10.1038/s41436-020-0931-1. [PMID] 32747766.
2020
Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.
JACC. Cardiovascular interventions. 13(5):606-617 [DOI] 10.1016/j.jcin.2020.01.226. [PMID] 32139218.
2020
Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial.
Trials. 21(1) [DOI] 10.1186/s13063-020-04859-1. [PMID] 33234137.
2020
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
Thrombosis and haemostasis. 120(8):1147-1158 [DOI] 10.1055/s-0040-1713376. [PMID] 32594508.
2020
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
Nature Reviews Cardiology. 17(4):242-257 [DOI] 10.1038/s41569-019-0314-y.
2020
Duration of Dual Antiplatelet Therapy After PCI: How Short Can We Go?
JACC. Cardiovascular interventions. 13(19):2263-2265 [DOI] 10.1016/j.jcin.2020.07.005. [PMID] 32950420.
2020
Editorial commentary: Evolving paradigms in antithrombotic therapy for patients with coronary artery disease undergoing percutaneous coronary intervention.
Trends in cardiovascular medicine. 30(4):203-204 [DOI] 10.1016/j.tcm.2019.06.004. [PMID] 31230913.
2020
Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment–Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention
Circulation. 142(24):2316-2328 [DOI] 10.1161/circulationaha.120.051532.
2020
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thrombosis and haemostasis. 120(1):83-93 [DOI] 10.1055/s-0039-1695772. [PMID] 31470444.
2020
Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in medicine : official journal of the American College of Medical Genetics. 22(11):1898-1902 [DOI] 10.1038/s41436-020-0894-2. [PMID] 32678355.
2020
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
American heart journal. 228:1-7 [DOI] 10.1016/j.ahj.2020.07.005. [PMID] 32739652.
2020
Fractional Flow Reserve-Based Coronary Artery Bypass Surgery: Current Evidence and Future Directions.
JACC. Cardiovascular interventions. 13(9):1086-1096 [DOI] 10.1016/j.jcin.2019.12.017. [PMID] 32222443.
2020
Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial.
Clinical research in cardiology : official journal of the German Cardiac Society. 109(7):930-943 [DOI] 10.1007/s00392-019-01586-9. [PMID] 31925529.
2020
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
Journal of the American Heart Association. 9(24) [DOI] 10.1161/jaha.120.018897.
2020
Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies.
Circulation. 141(11):891-901 [DOI] 10.1161/CIRCULATIONAHA.119.041619. [PMID] 31992063.
2020
Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery: A Meta-analysis.
JAMA internal medicine. 180(12):1638-1646 [DOI] 10.1001/jamainternmed.2020.4748. [PMID] 33044497.
2020
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention
Circulation. 142(15):1500-1502 [DOI] 10.1161/circulationaha.120.048770.
2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
Journal of the American Heart Association. 9(8) [DOI] 10.1161/jaha.120.015865.
2020
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.
European heart journal. 41(33):3132-3140 [DOI] 10.1093/eurheartj/ehz807. [PMID] 31994703.
2020
Pooling the Evidence at the Patient Level: End of the Bivalirudin Saga?
Thrombosis and haemostasis. 120(2):191-193 [DOI] 10.1055/s-0039-3400743. [PMID] 31899923.
2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.
JACC. Basic to translational science. 5(5):419-428 [DOI] 10.1016/j.jacbts.2020.02.009. [PMID] 32478205.
2020
Radial versus femoral and bivalirudin versus unfractionated heparin in vulnerable patients with acute coronary syndromes.
Revista espanola de cardiologia (English ed.). 73(11):874-876 [DOI] 10.1016/j.rec.2020.05.003. [PMID] 32513627.
2020
Reply: P2Y12 Inhibitor-Based Monotherapy: Optimal Duration and Ideal Agent.
Journal of the American College of Cardiology. 76(10):1274-1275 [DOI] 10.1016/j.jacc.2020.07.018. [PMID] 32883424.
2020
Safety and Efficacy of Double Antithrombotic Therapy With Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Journal of the American Heart Association. 9(16) [DOI] 10.1161/jaha.120.017212.
2020
Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development.
Expert opinion on investigational drugs. 29(6):537-546 [DOI] 10.1080/13543784.2020.1764533. [PMID] 32396484.
2020
Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies.
Journal of the American Heart Association. 9(7) [DOI] 10.1161/JAHA.119.014611. [PMID] 32223396.
2020
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS
European Heart Journal. 41(37):3533-3545 [DOI] 10.1093/eurheartj/ehaa670.
2020
Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial.
Cardiovascular diabetology. 19(1) [DOI] 10.1186/s12933-020-01153-x. [PMID] 33066794.
2020
Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial.
Cardiovascular research. 116(7):e70-e72 [DOI] 10.1093/cvr/cvaa120. [PMID] 32406492.
2020
Ticagrelor or Clopidogrel in Elderly Patients With Myocardial Infarction
Circulation. 142(18):1709-1712 [DOI] 10.1161/circulationaha.120.050845.
2020
Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial.
Journal of the American College of Cardiology. 76(21):2569-2571 [DOI] 10.1016/j.jacc.2020.09.586. [PMID] 33213734.
2020
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus.
JACC. Cardiovascular interventions. 13(19):2238-2247 [DOI] 10.1016/j.jcin.2020.07.032. [PMID] 33032712.
2020
Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Journal of the American College of Cardiology. 76(21):2436-2446 [DOI] 10.1016/j.jacc.2020.09.584. [PMID] 33213722.
2020
Ticagrelor or Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Circulation. 142(24):2329-2337 [DOI] 10.1161/circulationaha.120.050244.
2020
Ticagrelor With or Without Aspirin After Complex PCI.
Journal of the American College of Cardiology. 75(19):2414-2424 [DOI] 10.1016/j.jacc.2020.03.011. [PMID] 32240761.
2020
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.
Journal of the American College of Cardiology. 75(6):578-586 [DOI] 10.1016/j.jacc.2019.11.056. [PMID] 32057371.
2020
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
Journal of the American College of Cardiology. 75(19):2403-2413 [DOI] 10.1016/j.jacc.2020.03.008. [PMID] 32240760.
2020
Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.
Journal of the American College of Cardiology. 76(21):2450-2459 [DOI] 10.1016/j.jacc.2020.08.053. [PMID] 32882390.
2020
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel.
Journal of the American College of Cardiology. 76(12):1468-1483 [DOI] 10.1016/j.jacc.2020.06.085. [PMID] 32943165.
2020
Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients.
Journal of the American College of Cardiology. 75(21):2711-2722 [DOI] 10.1016/j.jacc.2020.03.070. [PMID] 32466887.
2020
When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y 12 Inhibition Induced by Ticagrelor
Journal of the American Heart Association. 9(24) [DOI] 10.1161/jaha.120.019432.
2019
Anticoagulation, the Unknown of the Antithrombotic Equation After Stenting of an Acute Coronary Syndrome.
Journal of the American College of Cardiology. 73(7):775-778 [DOI] 10.1016/j.jacc.2018.12.022. [PMID] 30784670.
2019
Aspirin for the primary prevention of cardiovascular disease: latest evidence.
Expert review of cardiovascular therapy. 17(9):633-643 [DOI] 10.1080/14779072.2019.1651199. [PMID] 31382819.
2019
Aspirin-Dependent Effects on Purinergic P2Y1 Receptor Expression.
Thrombosis and haemostasis. 119(5):726-734 [DOI] 10.1055/s-0039-1678707. [PMID] 30759486.
2019
Atrial fibrillation, with ACS and PCI: walking a tightrope.
European heart journal. 40(19):1563-1566 [DOI] 10.1093/eurheartj/ehz192. [PMID] 30957836.
2019
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
JAMA cardiology. 4(11):1092-1101 [DOI] 10.1001/jamacardio.2019.3355. [PMID] 31557763.
2019
Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms.
Expert opinion on drug safety. 18(12):1171-1189 [DOI] 10.1080/14740338.2019.1680637. [PMID] 31623473.
2019
De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis.
Journal of thrombosis and thrombolysis. 48(1):1-10 [DOI] 10.1007/s11239-019-01860-7. [PMID] 31004312.
2019
De-escalation of oral P2Y12 inhibitors guided by platelet function testing in ACS patients undergoing PCI: impact of diabetes mellitus.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 15(6):e486-e489 [DOI] 10.4244/EIJV15I6A89. [PMID] 31395576.
2019
Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.
Circulation. 140(3):240-261 [DOI] 10.1161/CIRCULATIONAHA.119.040167. [PMID] 31116032.
2019
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.
European heart journal. 40(31):2632-2653 [DOI] 10.1093/eurheartj/ehz372. [PMID] 31116395.
2019
Dual antithrombotic therapy for atrial fibrillation and PCI.
Lancet (London, England). 394(10206):1300-1302 [DOI] 10.1016/S0140-6736(19)31954-3. [PMID] 31492502.
2019
Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
JACC. Cardiovascular interventions. 12(16):1538-1549 [DOI] 10.1016/j.jcin.2019.05.028. [PMID] 31377269.
2019
Emergency Consent: Patients’ and Surrogates’ Perspectives on Consent for Clinical Trials in Acute Stroke and Myocardial Infarction.
Journal of the American Heart Association. 8(2) [DOI] 10.1161/JAHA.118.010905. [PMID] 30663498.
2019
Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting
Therapeutic Advances in Cardiovascular Disease. 13 [DOI] 10.1177/1753944719891688. [PMID] 31814532.
2019
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial.
Journal of the American Heart Association. 8(6) [DOI] 10.1161/JAHA.118.011139. [PMID] 30857464.
2019
Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
Therapeutic Advances in Cardiovascular Disease. 13 [DOI] 10.1177/1753944719893274. [PMID] 31823688.
2019
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.
Journal of the American College of Cardiology. 74(1):83-99 [DOI] 10.1016/j.jacc.2019.05.016. [PMID] 31272556.
2019
Oral Anticoagulation After TAVR in Patients With Atrial Fibrillation: The Certainty of Uncertainty.
JACC. Cardiovascular interventions. 12(16):1577-1579 [DOI] 10.1016/j.jcin.2019.04.014. [PMID] 31202953.
2019
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC. Basic to translational science. 4(7):763-775 [DOI] 10.1016/j.jacbts.2019.07.011. [PMID] 31998847.
2019
Pharmacodynamics During Transition Between Platelet P2Y12 Inhibiting Therapies.
Interventional cardiology clinics. 8(4):321-340 [DOI] 10.1016/j.iccl.2019.05.001. [PMID] 31445718.
2019
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.
British journal of clinical pharmacology. 85(2):413-421 [DOI] 10.1111/bcp.13812. [PMID] 30414387.
2019
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study
Journal of Thrombosis and Thrombolysis. 48(4):554-562 [DOI] 10.1007/s11239-019-01933-7. [PMID] 31420787.
2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation. 139(14):1661-1670 [DOI] 10.1161/CIRCULATIONAHA.118.038317. [PMID] 30630341.
2019
Pre-Treatment With Oral P2Y12 Inhibitors in Acute Coronary Syndromes Without ST-Segment Elevation: The Saga Continues.
Journal of the American College of Cardiology. 73(8):915-918 [DOI] 10.1016/j.jacc.2018.12.038. [PMID] 30819359.
2019
Reply: Platelet Function and Genetic Testing in Patients Receiving Oral Anticoagulation and Antiplatelet Treatment: An Area of Unmet Need.
JACC. Cardiovascular interventions. 12(18):1868-1869 [DOI] 10.1016/j.jcin.2019.07.040. [PMID] 31537291.
2019
Reply: Therapeutic Window of P2Y12 Inhibition: Should the Current Limits Be Modified?
JACC. Cardiovascular interventions. 12(23):2434-2435 [DOI] 10.1016/j.jcin.2019.10.015. [PMID] 31806222.
2019
Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations
Therapeutic Advances in Hematology. 10 [DOI] 10.1177/2040620719861475. [PMID] 31321012.
2019
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC).
European heart journal. 40(25):2070-2085 [DOI] 10.1093/eurheartj/ehy377. [PMID] 29992264.
2019
Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes.
Journal of the American Heart Association. 8(13) [DOI] 10.1161/JAHA.119.013032. [PMID] 31242821.
2019
Systematic Evaluation of the Robustness of the Evidence Supporting Current Guidelines on Myocardial Revascularization Using the Fragility Index.
Circulation. Cardiovascular quality and outcomes. 12(12) [DOI] 10.1161/CIRCOUTCOMES.119.006017. [PMID] 31822120.
2019
Tailoring Antiplatelet Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement: Navigating the Unknown.
JACC. Cardiovascular interventions. 12(1):33-37 [DOI] 10.1016/j.jcin.2018.10.047. [PMID] 30621975.
2019
Tailoring P2Y12 Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Journal of the American Heart Association. 8(18) [DOI] 10.1161/JAHA.119.014000. [PMID] 31538837.
2019
The Conundrum Surrounding Racial Differences on Ischaemic and Bleeding Risk with Dual Anti-Platelet Therapy.
Thrombosis and haemostasis. 119(1):9-13 [DOI] 10.1055/s-0038-1676612. [PMID] 30597496.
2019
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
American heart journal. 208:81-90 [DOI] 10.1016/j.ahj.2018.11.008. [PMID] 30580130.
2019
Three-Dimensional Echocardiography for Transcatheter Aortic Valve Replacement Sizing: A Systematic Review and Meta-Analysis.
Journal of the American Heart Association. 8(19) [DOI] 10.1161/JAHA.119.013463. [PMID] 31549579.
2019
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
The New England journal of medicine. 381(16):1524-1534 [DOI] 10.1056/NEJMoa1908973. [PMID] 31475799.
2019
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
The New England journal of medicine. 381(21):2032-2042 [DOI] 10.1056/NEJMoa1908419. [PMID] 31556978.
2019
Tug of War Between Dual and Triple Antithrombotic Therapy in Atrial Fibrillation/PCI Patients With CKD.
JACC. Cardiovascular interventions. 12(16):1562-1565 [DOI] 10.1016/j.jcin.2019.06.032. [PMID] 31439337.
2019
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions. 12(16):1521-1537 [DOI] 10.1016/j.jcin.2019.03.034. [PMID] 31202949.
2018
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2.
JACC. Cardiovascular interventions. 11(5):417-434 [DOI] 10.1016/j.jcin.2017.10.051. [PMID] 29519377.
2018
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.
Journal of the American College of Cardiology. 72(23 Pt A):2915-2931 [DOI] 10.1016/j.jacc.2018.09.057. [PMID] 30522654.
2018
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
Circulation. 138(5):527-536 [DOI] 10.1161/CIRCULATIONAHA.118.034722. [PMID] 30571525.
2018
Aspirin for primary prevention of cardiovascular disease.
Lancet (London, England). 392(10152):988-990 [DOI] 10.1016/S0140-6736(18)31990-1. [PMID] 30158070.
2018
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.
Nature reviews. Cardiology. 15(8):480-496 [DOI] 10.1038/s41569-018-0049-1. [PMID] 29973709.
2018
Canakinumab for secondary prevention of atherosclerotic disease.
Expert opinion on biological therapy. 18(2):215-220 [DOI] 10.1080/14712598.2018.1420776. [PMID] 29265905.
2018
Cardiorenal Safety of OTC Analgesics.
Journal of cardiovascular pharmacology and therapeutics. 23(2):103-118 [DOI] 10.1177/1074248417751070. [PMID] 29421936.
2018
Cigarette smoking reduces platelet reactivity independently of clopidogrel treatment in patients with non-ST elevation acute coronary syndromes.
Platelets. 29(3):309-311 [DOI] 10.1080/09537104.2017.1394452. [PMID] 29206072.
2018
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
Journal of translational medicine. 16(1) [DOI] 10.1186/s12967-018-1469-8. [PMID] 29642909.
2018
CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction.
Expert opinion on investigational drugs. 27(12):997-1005 [DOI] 10.1080/13543784.2018.1543399. [PMID] 30376729.
2018
Diabetes and antiplatelet therapy: from bench to bedside.
Cardiovascular diagnosis and therapy. 8(5):594-609 [DOI] 10.21037/cdt.2018.05.09. [PMID] 30498684.
2018
Effect of a Contrast Modulation System on Contrast Media Use and the Rate of Acute Kidney Injury After Coronary Angiography.
JACC. Cardiovascular interventions. 11(16):1601-1610 [DOI] 10.1016/j.jcin.2018.04.007. [PMID] 30139467.
2018
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy.
Progress in cardiovascular diseases. 60(4-5):478-490 [DOI] 10.1016/j.pcad.2017.12.004. [PMID] 29291426.
2018
Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease.
Expert opinion on drug safety. 17(10):1041-1052 [DOI] 10.1080/14740338.2018.1524869. [PMID] 30223690.
2018
High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome – Insight from the GEPRESS study.
International journal of cardiology. 259:20-25 [DOI] 10.1016/j.ijcard.2018.01.057. [PMID] 29579602.
2018
Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet Reactivity.
Thrombosis and haemostasis. 118(3):490-501 [DOI] 10.1055/s-0038-1629920. [PMID] 29448294.
2018
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Circulation. Cardiovascular interventions. 11(4) [DOI] 10.1161/CIRCINTERVENTIONS.117.005635. [PMID] 29632238.
2018
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.
Blood advances. 2(6):715-730 [DOI] 10.1182/bloodadvances.2017013573. [PMID] 29588304.
2018
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Clinical pharmacology and therapeutics. 104(4):664-674 [DOI] 10.1002/cpt.1006. [PMID] 29280137.
2018
P2Y12-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes.
Circulation. 138(15):1582-1596 [DOI] 10.1161/CIRCULATIONAHA.118.032078. [PMID] 30354508.
2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Circulation. 137(23):2450-2462 [DOI] 10.1161/CIRCULATIONAHA.118.033983. [PMID] 29526833.
2018
Pharmacogenomic Testing to Select Antiplatelet Therapy.
Journal of the American College of Cardiology. 71(17):1878-1881 [DOI] 10.1016/j.jacc.2018.03.021. [PMID] 29699613.
2018
Platelet Function or Genetic Testing for Guiding De-Escalation of Anti-Platelet Therapy: The Jury is Still Out.
Thrombosis and haemostasis. 118(9):1509-1511 [DOI] 10.1055/s-0038-1668546. [PMID] 30114718.
2018
Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study.
Clinical cardiology. 41(8):1004-1008 [DOI] 10.1002/clc.22988. [PMID] 30033595.
2018
Response by Angiolillo et al to Letter Regarding Article, “International Expert Consensus Document on Switching Platelet P2Y12 Receptor Inhibiting Therapies”.
Circulation. 137(21):2310-2311 [DOI] 10.1161/CIRCULATIONAHA.118.033779. [PMID] 29784690.
2018
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
Journal of cardiovascular pharmacology and therapeutics. 23(1):23-37 [DOI] 10.1177/1074248417708617. [PMID] 28565918.
2018
Role of genetic testing in patients undergoing percutaneous coronary intervention.
Expert review of clinical pharmacology. 11(2):151-164 [DOI] 10.1080/17512433.2017.1353909. [PMID] 28689434.
2018
Switching antiplatelet therapy in real-world clinical practice.
Cardiovascular revascularization medicine : including molecular interventions. 19(8):897-898 [DOI] 10.1016/j.carrev.2018.11.009. [PMID] 30551835.
2018
Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes.
Platelets. 29(5):528-530 [DOI] 10.1080/09537104.2018.1457782. [PMID] 29617211.
2018
The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.
Expert review of hematology. 11(1):5-12 [DOI] 10.1080/17474086.2018.1400378. [PMID] 29091481.
2018
The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCI.
Journal of the American College of Cardiology. 71(11):1243-1245 [DOI] 10.1016/j.jacc.2018.01.040. [PMID] 29544608.
2018
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.
Journal of the American College of Cardiology. 71(5):489-496 [DOI] 10.1016/j.jacc.2017.11.050. [PMID] 29406853.
2018
Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial.
American heart journal. 204:205-209 [DOI] 10.1016/j.ahj.2018.07.013. [PMID] 30149889.
2018
Vascular access and antithrombotic therapy in patients with acute coronary syndrome.
Lancet (London, England). 392(10150):801-802 [DOI] 10.1016/S0140-6736(18)31921-4. [PMID] 30153987.
2017
Antiplatelet and Anticoagulation Therapy in Percutaneous Coronary Intervention.
Interventional cardiology clinics. 6(1):xi-xii [DOI] 10.1016/j.iccl.2016.10.001. [PMID] 27886826.
2017
Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions.
JACC. Cardiovascular interventions. 10(5):425-437 [DOI] 10.1016/j.jcin.2016.12.279. [PMID] 28279311.
2017
Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: Results of the surgery after stenting registry.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 89(1):E13-E25 [DOI] 10.1002/ccd.26629. [PMID] 27404797.
2017
Antithrombotic therapy for acute coronary syndrome: Past, present and future.
Thrombosis and haemostasis. 117(7):1240-1248 [DOI] 10.1160/TH16-12-0963. [PMID] 28594051.
2017
Antithrombotic therapy for patients with STEMI undergoing primary PCI.
Nature reviews. Cardiology. 14(6):361-379 [DOI] 10.1038/nrcardio.2017.18. [PMID] 28230176.
2017
Antithrombotic Therapy for Prevention of Cerebral Thromboembolic Events After Transcatheter Aortic Valve Replacement: Evolving Paradigms and Ongoing Directions.
JACC. Cardiovascular interventions. 10(13):1366-1369 [DOI] 10.1016/j.jcin.2017.05.005. [PMID] 28527775.
2017
Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease).
Circulation. Cardiovascular interventions. 10(2) [DOI] 10.1161/CIRCINTERVENTIONS.116.004368. [PMID] 28193678.
2017
Clinical Pharmacology and Cardiovascular Safety of Naproxen.
American journal of cardiovascular drugs : drugs, devices, and other interventions. 17(2):97-107 [DOI] 10.1007/s40256-016-0200-5. [PMID] 27826802.
2017
Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor.
The American journal of cardiology. 119(8):1135-1140 [DOI] 10.1016/j.amjcard.2017.01.002. [PMID] 28202132.
2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
Thrombosis and haemostasis. 117(5):940-947 [DOI] 10.1160/TH16-09-0703. [PMID] 28300867.
2017
Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 12(14):1681-1683 [DOI] 10.4244/EIJV12I14A276. [PMID] 28216470.
2017
Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y12 Receptor Inhibitors: How Real Is It?
JACC. Cardiovascular interventions. 10(2):130-132 [DOI] 10.1016/j.jcin.2016.11.021. [PMID] 28104205.
2017
Dual antiplatelet therapy guided by platelet function testing.
Lancet (London, England). 390(10104):1718-1720 [DOI] 10.1016/S0140-6736(17)32279-1. [PMID] 28855079.
2017
Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome.
Journal of thrombosis and thrombolysis. 44(3):355-361 [DOI] 10.1007/s11239-017-1541-x. [PMID] 28840456.
2017
Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.
Journal of the American College of Cardiology. 69(6):603-612 [DOI] 10.1016/j.jacc.2016.11.050. [PMID] 28089180.
2017
Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus.
Thrombosis and haemostasis. 117(1):201-203 [DOI] 10.1160/TH16-08-0594. [PMID] 27786340.
2017
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Journal of the American Heart Association. 6(4) [DOI] 10.1161/JAHA.117.005650. [PMID] 28356282.
2017
Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 89(2):190-198 [DOI] 10.1002/ccd.26428. [PMID] 26909669.
2017
Institutional profile: University of Florida Health Personalized Medicine Program.
Pharmacogenomics. 18(5):421-426 [DOI] 10.2217/pgs-2017-0028. [PMID] 28346068.
2017
International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies.
Circulation. 136(20):1955-1975 [DOI] 10.1161/CIRCULATIONAHA.117.031164. [PMID] 29084738.
2017
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Ticagrelor-Treated Patients.
JACC. Cardiovascular interventions. 10(13):1374-1375 [DOI] 10.1016/j.jcin.2017.04.027. [PMID] 28683943.
2017
Oral trans-mucosal administration of ticagrelor: is this really the future?
Thrombosis and haemostasis. 117(5):826-828 [DOI] 10.1160/TH17-03-0177. [PMID] 28331923.
2017
Percutaneous Interventional Repair of an Intraoperative Right Coronary Artery Tear.
JACC. Cardiovascular interventions. 10(23):2464-2465 [DOI] 10.1016/j.jcin.2017.07.039. [PMID] 29153495.
2017
Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome.
Journal of thrombosis and thrombolysis. 44(2):145-153 [DOI] 10.1007/s11239-017-1516-y. [PMID] 28608165.
2017
Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention: When and Which Drugs?
Interventional cardiology clinics. 6(1):13-24 [DOI] 10.1016/j.iccl.2016.08.002. [PMID] 27886816.
2017
Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis?
Journal of the American College of Cardiology. 69(23) [DOI] 10.1016/j.jacc.2017.03.599. [PMID] 28595709.
2017
Reply: Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology. 69(2):250-251 [DOI] 10.1016/j.jacc.2016.09.982. [PMID] 28081837.
2017
Should endovascular approach be the first line of treatment for retroperitoneal bleeding with hemodynamic shock following percutaneous intervention? A case series.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 90(1):104-111 [DOI] 10.1002/ccd.26775. [PMID] 27566914.
2017
Switching P2Y12 Receptor Inhibiting Therapies.
Interventional cardiology clinics. 6(1):67-89 [DOI] 10.1016/j.iccl.2016.08.006. [PMID] 27886824.
2017
Tailoring duration of DAPT with risk scores.
Lancet (London, England). 389(10073):987-989 [DOI] 10.1016/S0140-6736(17)30591-3. [PMID] 28291000.
2017
The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.
American journal of cardiovascular drugs : drugs, devices, and other interventions. 17(2):109-121 [DOI] 10.1007/s40256-016-0202-3. [PMID] 27854064.
2017
The role of oral anticoagulant therapy in patients with acute coronary syndrome.
Therapeutic advances in hematology. 8(12):353-366 [DOI] 10.1177/2040620717733691. [PMID] 29204262.
2017
Triple Antithrombotic Therapy at the Intercept Between Threats and Opportunities: Don’t Throw Out the Baby With the Bath Water.
JACC. Cardiovascular interventions. 10(11):1086-1088 [DOI] 10.1016/j.jcin.2017.03.028. [PMID] 28527777.
2017
Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery.
Journal of the American College of Cardiology. 69(14):1861-1870 [DOI] 10.1016/j.jacc.2017.02.012. [PMID] 28385315.
2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
European heart journal. 37(35):2722-30 [DOI] 10.1093/eurheartj/ehv744. [PMID] 26848148.
2016
A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Expert opinion on drug safety. 15(2):275-85 [DOI] 10.1517/14740338.2016.1133585. [PMID] 26680584.
2016
Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease.
Circulation journal : official journal of the Japanese Circulation Society. 80(4):791-801 [DOI] 10.1253/circj.CJ-16-0208. [PMID] 26984587.
2016
Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease.
Nature reviews. Cardiology. 13(10):609-22 [DOI] 10.1038/nrcardio.2016.111. [PMID] 27489191.
2016
Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus.
Circulation. 134(20):1579-1594 [PMID] 27729421.
2016
Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology. 67(17):1994-2004 [DOI] 10.1016/j.jacc.2016.02.045. [PMID] 27012781.
2016
Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions. 9(3):228-230 [DOI] 10.1016/j.jcin.2015.11.022. [PMID] 26777325.
2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Thrombosis and haemostasis. 116(1):69-77 [DOI] 10.1160/TH15-12-0981. [PMID] 27009617.
2016
Dual antiplatelet therapy after coronary stenting.
Expert opinion on pharmacotherapy. 17(13):1775-87 [DOI] 10.1080/14656566.2016.1202924. [PMID] 27309035.
2016
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Thrombosis and haemostasis. 115(3):622-31 [DOI] 10.1160/TH15-06-0467. [PMID] 26633836.
2016
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Journal of the American College of Cardiology. 67(6):603-613 [DOI] 10.1016/j.jacc.2015.11.044. [PMID] 26868683.
2016
Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
European heart journal. Acute cardiovascular care. 5(5):475-86 [DOI] 10.1177/2048872615624849. [PMID] 26758542.
2016
Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors.
Thrombosis and haemostasis. 116(6):1060-1069 [PMID] 27488362.
2016
Intracoronary Bivalirudin Bolus in ST-Elevation Myocardial Infarction Patients Treated with Primary Angioplasty: Theoretical Bases, Clinical Experience, and Future Applications.
American journal of cardiovascular drugs : drugs, devices, and other interventions. 16(6):391-397 [PMID] 27541144.
2016
Intracoronary vs intravenous bivalirudin bolus in ST-elevation myocardial infarction patients treated with primary angioplasty.
European heart journal. Acute cardiovascular care. 5(5):487-96 [DOI] 10.1177/2048872615594499. [PMID] 26163529.
2016
New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban.
International journal of cardiology. 225:154-158 [DOI] 10.1016/j.ijcard.2016.09.125. [PMID] 27723533.
2016
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Circulation. 134(11):780-92 [DOI] 10.1161/CIRCULATIONAHA.116.023402. [PMID] 27559041.
2016
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
JACC. Cardiovascular interventions. 9(11):1089-98 [DOI] 10.1016/j.jcin.2016.02.039. [PMID] 27013060.
2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
Journal of the American College of Cardiology. 67(10):1145-1154 [DOI] 10.1016/j.jacc.2015.12.062. [PMID] 26965534.
2016
Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.
Journal of the American College of Cardiology. 67(23):2732-2740 [DOI] 10.1016/j.jacc.2016.03.529. [PMID] 27046160.
2016
Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 12(3):312-8 [DOI] 10.4244/EIJV12I3A51. [PMID] 27320425.
2016
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
Expert review of cardiovascular therapy. 14(7):811-20 [DOI] 10.1586/14779072.2016.1164035. [PMID] 26953527.
2016
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
Heart (British Cardiac Society). 102(8):617-25 [DOI] 10.1136/heartjnl-2015-308963. [PMID] 26848185.
2016
Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
Nature reviews. Cardiology. 13(1):11-27 [DOI] 10.1038/nrcardio.2015.113. [PMID] 26283269.
2016
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
American heart journal. 182:125-134 [DOI] 10.1016/j.ahj.2016.09.006. [PMID] 27914492.
2016
Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction.
Trends in cardiovascular medicine. 26(4):321-34 [DOI] 10.1016/j.tcm.2015.08.002. [PMID] 26391344.
2016
Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data.
Thrombosis and haemostasis. 115(4):844-55 [DOI] 10.1160/TH15-09-0742. [PMID] 26607655.
2015
[Non-cardiac surgery in patients with previous percutaneous coronary intervention according to the 2014 European guidelines].
Giornale italiano di cardiologia (2006). 16(5):277-80 [DOI] 10.1714/1870.20424. [PMID] 25994462.
2015
A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.
Journal of thrombosis and thrombolysis. 39(1):8-14 [DOI] 10.1007/s11239-014-1135-9. [PMID] 25305090.
2015
Acute coronary syndromes: applying practice guidelines and defining the unmet need in clinical practice.
The American journal of cardiology. 115(5 Suppl):1A-2A [DOI] 10.1016/j.amjcard.2015.01.001. [PMID] 25728970.
2015
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
European heart journal. 36(27):1762-71 [DOI] 10.1093/eurheartj/ehv104. [PMID] 25896078.
2015
Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study.
Circulation. Cardiovascular interventions. 8(6) [DOI] 10.1161/CIRCINTERVENTIONS.114.001712. [PMID] 26025216.
2015
Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) study.
Journal of thrombosis and thrombolysis. 40(3):331-9 [DOI] 10.1007/s11239-015-1203-9. [PMID] 25761430.
2015
Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention.
Circulation. Cardiovascular interventions. 8(6) [DOI] 10.1161/CIRCINTERVENTIONS.115.002760. [PMID] 26056251.
2015
Drug-drug interactions between clopidogrel and novel cardiovascular drugs.
European journal of pharmacology. 765:332-6 [DOI] 10.1016/j.ejphar.2015.08.059. [PMID] 26341013.
2015
Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery.
Thrombosis and haemostasis. 114(2):423-31 [DOI] 10.1160/TH14-12-1057. [PMID] 26017898.
2015
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
Journal of thrombosis and thrombolysis. 40(3):317-22 [DOI] 10.1007/s11239-015-1233-3. [PMID] 26024789.
2015
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
JACC. Cardiovascular interventions. 8(11):1457-1467 [DOI] 10.1016/j.jcin.2015.02.030. [PMID] 26404199.
2015
Impact of impaired glucose tolerance on clopidogrel response in patients with coronary artery disease.
Journal of thrombosis and thrombolysis. 40(2):174-81 [DOI] 10.1007/s11239-015-1177-7. [PMID] 25633821.
2015
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
Journal of the American Heart Association. 4(8) [DOI] 10.1161/JAHA.115.002171. [PMID] 26307570.
2015
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
European heart journal. 36(20):1252-63 [DOI] 10.1093/eurheartj/ehu523. [PMID] 25616646.
2015
Management of adjunctive antithrombotic therapy in STEMI patients treated with fibrinolysis undergoing rescue or delayed PCI.
Thrombosis and haemostasis. 114(5):945-57 [DOI] 10.1160/TH15-03-0204. [PMID] 26202745.
2015
Novel antiplatelet agents in acute coronary syndrome.
Nature reviews. Cardiology. 12(1):30-47 [DOI] 10.1038/nrcardio.2014.156. [PMID] 25286881.
2015
Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.
Progress in cardiovascular diseases. 58(3):267-77 [DOI] 10.1016/j.pcad.2015.08.009. [PMID] 26277706.
2015
Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemma.
Journal of thrombosis and thrombolysis. 39(2):203-8 [DOI] 10.1007/s11239-014-1132-z. [PMID] 25164314.
2015
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Thrombosis and haemostasis. 113(2):272-82 [DOI] 10.1160/TH14-05-0436. [PMID] 25274620.
2015
Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
JACC. Cardiovascular interventions. 8(8):1075-1083 [DOI] 10.1016/j.jcin.2015.02.022. [PMID] 26117466.
2015
Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus.
Cardiovascular revascularization medicine : including molecular interventions. 16(8):450-4 [DOI] 10.1016/j.carrev.2015.08.007. [PMID] 26440227.
2015
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
Future cardiology. 11(5):547-64 [DOI] 10.2217/fca.15.50. [PMID] 26406386.
2015
Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratory.
Cardiovascular revascularization medicine : including molecular interventions. 16(5):266-71 [DOI] 10.1016/j.carrev.2015.05.011. [PMID] 26242981.
2015
Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy.
International journal of cardiology. 199:319-25 [DOI] 10.1016/j.ijcard.2015.07.064. [PMID] 26241637.
2015
Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines.
Circulation. Cardiovascular interventions. 8(3) [DOI] 10.1161/CIRCINTERVENTIONS.114.002301. [PMID] 25717045.
2015
Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention.
Journal of the American College of Cardiology. 65(16):1714-1715 [DOI] 10.1016/j.jacc.2014.12.069. [PMID] 25908082.
2015
Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists.
Journal of thrombosis and thrombolysis. 40(1):118-25 [DOI] 10.1007/s11239-014-1130-1. [PMID] 25129122.
2015
Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
Circulation. Cardiovascular interventions. 8(7) [DOI] 10.1161/CIRCINTERVENTIONS.114.002232. [PMID] 26152562.
2015
Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.
Circulation. 131(12):1047-53 [DOI] 10.1161/CIRCULATIONAHA.114.013774. [PMID] 25681464.
2014
Aspirin treatment and outcomes in patients undergoing percutaneous coronary intervention: is there a role for pharmacodynamic testing?
Journal of the American College of Cardiology. 64(9):872-4 [DOI] 10.1016/j.jacc.2014.06.1157. [PMID] 25169170.
2014
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Journal of cardiovascular translational research. 7(1):53-63 [DOI] 10.1007/s12265-013-9535-3. [PMID] 24395495.
2014
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification.
Journal of thrombosis and haemostasis : JTH. 12(4):560-3 [DOI] 10.1111/jth.12505. [PMID] 24428754.
2014
Effect of an optimized treatment with insulin on platelet reactivity after discharge in patients with an acute coronary syndrome and hyperglycemia.
Revista espanola de cardiologia (English ed.). 67(1):22-7 [DOI] 10.1016/j.rec.2013.05.020. [PMID] 24774260.
2014
Erratum to: Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Journal of thrombosis and thrombolysis. 37(3) [DOI] 10.1007/s11239-013-1003-z. [PMID] 24101257.
2014
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.
Journal of thrombosis and thrombolysis. 38(2):127-36 [DOI] 10.1007/s11239-013-0987-8. [PMID] 24043374.
2014
Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease.
Journal of cardiovascular translational research. 7(1):47-52 [DOI] 10.1007/s12265-013-9530-8. [PMID] 24357254.
2014
Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies.
Journal of thrombosis and thrombolysis. 38(1):11-23 [DOI] 10.1007/s11239-013-1035-4. [PMID] 24368727.
2014
Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
JACC. Cardiovascular interventions. 7(10):1117-27 [DOI] 10.1016/j.jcin.2014.04.020. [PMID] 25240538.
2014
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).
Journal of the American College of Cardiology. 63(7):619-629 [DOI] 10.1016/j.jacc.2013.10.022. [PMID] 24184169.
2014
Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation.
Journal of cardiovascular translational research. 7(1):39-46 [DOI] 10.1007/s12265-013-9533-5. [PMID] 24362676.
2014
Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events).
Journal of the American College of Cardiology. 63(8):769-77 [DOI] 10.1016/j.jacc.2013.10.043. [PMID] 24239662.
2014
Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.
Journal of thrombosis and haemostasis : JTH. 12(2):126-37 [DOI] 10.1111/jth.12472. [PMID] 24298905.
2014
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Journal of the American College of Cardiology. 64(10):1005-14 [DOI] 10.1016/j.jacc.2014.06.1170. [PMID] 25190236.
2014
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Circulation. Cardiovascular interventions. 7(1):113-24 [DOI] 10.1161/CIRCINTERVENTIONS.113.001150. [PMID] 24550531.
2014
Operator radiation exposure and physical discomfort during a right versus left radial approach for coronary interventions: a randomized evaluation.
JACC. Cardiovascular interventions. 7(7):810-6 [DOI] 10.1016/j.jcin.2013.11.026. [PMID] 24954573.
2014
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.